{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:18:44Z","timestamp":1787635124946,"version":"build-2736575974"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether documented adherence to a prespecified risk-based antithrombotic management framework was associated with 30-day rebleeding, thromboembolism, and net adverse clinical events (NACE) after therapeutic endoscopy for non-variceal upper gastrointestinal bleeding (NVUGIB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective cohort included 150 unique index admissions from January 2021 through December 2025. Documented strategy adherence was coded in 100 patients and non-adherence in 50. Rebleeding was evaluated only after successful initial hemostasis (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f141). Parsimonious Firth penalized logistic regression was used for the primary analyses. Thirty multiple imputations by chained equations with predictive mean matching and propensity-score overlap weighting were used as sensitivity analyses. Resumption timing was analyzed descriptively because temporal ordering did not support causal modeling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-day rebleeding occurred in 13\/141 patients (9.2%), thromboembolism in 16\/150 (10.7%), death in 6\/150 (4.0%), and NACE in 29\/150 (19.3%). Rebleeding was observed in 5\/96 adherent patients (5.2%) and 8\/45 non-adherent patients (17.8%; Fisher\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.026); NACE occurred in 12\/100 (12.0%) and 17\/50 (34.0%), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.002). Documented adherence was associated with lower rebleeding (adjusted odds ratio [aOR] 0.03, 95% CI 0.002\u20130.43) and NACE (aOR 0.04, 95% CI 0.007\u20130.20). The corresponding adjusted risk differences were \u221215.7 percentage points (95% CI \u221223.1 to \u22129.0) and \u221227.4 percentage points (95% CI \u221234.2 to \u221217.1). Multiple-imputation and overlap-weighted analyses were directionally concordant. Seven of 13 rebleeding events occurred on or before the recorded resumption date.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Documented adherence to a risk-based management framework was associated with fewer 30-day adverse events. Because exposure classification depended on clinical documentation, residual confounding and misclassification remain likely, and the large adjusted effects should not be interpreted causally. Individualized multidisciplinary assessment appears more important than any single predefined resumption threshold.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1890670","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:23:33Z","timestamp":1787631813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Documented risk-based antithrombotic management and 30-day outcomes after endoscopic hemostasis for non-variceal upper gastrointestinal bleeding: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyun","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Second People\u2019s Hospital of Linfen","place":["Linfen, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Endoscopy, Xixian County People\u2019s Hospital","place":["Xixian, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Linfen Central Hospital","place":["Linfen, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.14309\/ajg.0000000000001627","article-title":"American College of Gastroenterology\u2013Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period","volume":"117","author":"Abraham","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7326\/M19-1795","article-title":"Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group","volume":"171","author":"Barkun","year":"2019","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1055\/a-1369-5274","article-title":"Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: ESGE guideline\u2014update 2021","volume":"53","author":"Gralnek","year":"2021","journal-title":"Endoscopy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1002\/bjs.9351","article-title":"Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding","volume":"101","author":"Lu","year":"2014","journal-title":"Br J Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12245-024-00649-7","article-title":"Evaluation and treatment of gastrointestinal bleeding in patients taking anticoagulants presenting to the emergency department","volume":"17","author":"Singer","year":"2024","journal-title":"Int J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.5152\/tjg.2022.22007","article-title":"The evolution of gastrointestinal bleeding: a holistic investigation of global outputs with bibliometric analysis","volume":"33","author":"Kudu","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1111\/jth.15476","article-title":"Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding","volume":"19","author":"Candeloro","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ajg.2014.398","article-title":"The risks of thromboembolism versus recurrent gastrointestinal bleeding after interruption of systemic anticoagulation","volume":"110","author":"Sengupta","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cgh.2020.11.029","article-title":"Restarting warfarin versus direct oral anticoagulants after major gastrointestinal bleeding and associated outcomes in atrial fibrillation","volume":"20","author":"Tapaskar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.54996\/anatolianjem.1603516","article-title":"Factors associated with thirty-day emergency department revisits for upper gastrointestinal bleeding: insights from a five-year retrospective study","volume":"8","author":"Kudu","year":"2025","journal-title":"Anatol J Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the Reporting of observational studies in epidemiology (STROBE) statement","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2288-14-75","article-title":"Tuning multiple imputation by predictive mean matching and local residual draws","volume":"14","author":"Morris","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:23:35Z","timestamp":1787631815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1890670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1890670"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1890670","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1890670"}}